Relative Predictive Value of Circulating Immune Markers in US Adults Without Cardiovascular Disease: Implications for Risk Reclassification.
Ambulatory Care
/ methods
Biomarkers
/ blood
C-Reactive Protein
/ analysis
Cardiovascular Diseases
/ blood
Classification
/ methods
Female
Follow-Up Studies
Heart Disease Risk Factors
Humans
Leukocyte Count
/ methods
Lymphocytes
/ immunology
Male
Middle Aged
Monocytes
/ immunology
Neutrophils
/ immunology
Predictive Value of Tests
United States
/ epidemiology
Journal
Mayo Clinic proceedings
ISSN: 1942-5546
Titre abrégé: Mayo Clin Proc
Pays: England
ID NLM: 0405543
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
12
07
2020
revised:
11
10
2020
accepted:
02
11
2020
pubmed:
13
4
2021
medline:
23
7
2021
entrez:
12
4
2021
Statut:
ppublish
Résumé
To investigate the relative predictive value of circulating immune cell markers for cardiovascular mortality in ambulatory adults without cardiovascular disease. We analyzed data of participants enrolled in the National Health and Nutrition Examination Survey from January 1, 1999, to December 31, 2010, with the total leukocyte count within a normal range (4000-11,000 cells/μL [to convert to cells ×10 Among 21,599 participants eligible for this analysis, the median age was 47 years (interquartile range, 34-63 years); 10,651 (49.2%) participants were women, and 10,713 (49.5%) were self-reported non-Hispanic white. During a median follow-up of 9.6 years (interquartile range, 6.8-13.1 years), there were 627 cardiovascular deaths. MLR had the best predictive value for cardiovascular mortality. The addition of elevated MLR (≥0.3) to the 10-year ASCVD risk score improved the classification by 2.7%±1.4% (P=.04). Elevated MLR had better predictive value than C-reactive protein and several components of the 10-year ASCVD risk score. Among ambulatory US adults without preexisting cardiovascular disease, we found that MLR had the best predictive value for cardiovascular mortality among circulating immune markers. The addition of MLR to the 10-year risk score significantly improved the risk classification of participants.
Identifiants
pubmed: 33840521
pii: S0025-6196(20)31389-6
doi: 10.1016/j.mayocp.2020.11.027
pmc: PMC8683138
mid: NIHMS1760264
pii:
doi:
Substances chimiques
Biomarkers
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1812-1821Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR003096
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL147549
Pays : United States
Organisme : BLRD VA
ID : I01 BX002706
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL157999
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL125735
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001417
Pays : United States
Informations de copyright
Published by Elsevier Inc.
Références
Stat Med. 2012 Oct 15;31(23):2676-86
pubmed: 22307964
J Exp Med. 2007 Nov 26;204(12):3037-47
pubmed: 18025128
Nat Rev Cardiol. 2020 May;17(5):269-285
pubmed: 31969688
N Engl J Med. 1974 Jun 6;290(23):1275-8
pubmed: 4827627
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Circulation. 2014 Jul 1;130(1):35-50
pubmed: 24982116
Immunol Res. 2012 Sep;53(1-3):41-57
pubmed: 22430559
JAMA Cardiol. 2018 Jun 1;3(6):455-462
pubmed: 29801037
JAMA. 1987 May 1;257(17):2318-24
pubmed: 3553628
Circulation. 1998 Aug 25;98(8):731-3
pubmed: 9727541
ESC Heart Fail. 2020 Aug;7(4):1676-1687
pubmed: 32424980
Atherosclerosis. 2007 Oct;194(2):e9-17
pubmed: 17194459
Circulation. 2008 Feb 12;117(6):743-53
pubmed: 18212285
J Am Heart Assoc. 2018 Feb 1;7(3):
pubmed: 29419389
Circulation. 2004 Jun 1;109(21 Suppl 1):II2-10
pubmed: 15173056
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
N Engl J Med. 1997 Apr 3;336(14):973-9
pubmed: 9077376
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12
pubmed: 17569110
Am J Cardiol. 2017 Sep 15;120(6):911-916
pubmed: 28779870
N Engl J Med. 2019 Dec 26;381(26):2497-2505
pubmed: 31733140
Circ Res. 2015 Mar 27;116(7):1254-68
pubmed: 25814686
Circulation. 1998 Jan 6-13;97(1):19-22
pubmed: 9443426
Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2045-51
pubmed: 22895665
Circ Res. 2016 Jun 24;119(1):91-112
pubmed: 27340270
Am J Epidemiol. 1998 May 15;147(10):969-77
pubmed: 9596475
Circulation. 2014 Jun 24;129(25 Suppl 2):S49-73
pubmed: 24222018
J Am Coll Cardiol. 2019 Dec 24;74(25):3136-3138
pubmed: 31856970
Am J Epidemiol. 1997 Mar 1;145(5):416-21
pubmed: 9048515
Circ Res. 2004 May 14;94(9):1203-10
pubmed: 15059935
Clin Immunol Immunopathol. 1980 Dec;17(4):506-14
pubmed: 7192197
Circulation. 1998 May 26;97(20):2007-11
pubmed: 9610529